Effect of manidipine, a new calcium antagonist, on intrarenal hemodynamics in essential hypertension. 1992

K Murakami, and G Kimura, and M Imanishi, and T Sanai, and Y Kawano, and S Kojima, and K Yoshida, and H Abe, and T Ashida, and H Yoshimi
Department of Medicine, National Cardiovascular Center, Osaka, Japan.

The effect of manidipine, a new Ca2+ antagonist, on intrarenal hemodynamics was assessed in essential hypertension and compared with nicardipine, a previously studied Ca2+ antagonist. Identical 2-week studies were repeated before and during the administration of manidipine (10 mg once daily, 2 weeks) in 3 patients with essential hypertension who were given regular- and sodium-restricted diets for 1 week each. The renal function curve (pressure-natriuresis relationship) was drawn by plotting the urinary sodium excretion rate on the y-axis as a function of the systemic mean arterial pressure (MAP) on the x-axis. Assuming that the difference between MAP and the extrapolated x-intercept of the renal function curve represents the effective filtration pressure across the glomerular capillary walls, the intrarenal hemodynamics were calculated (e.g., afferent arteriolar resistance (RA), efferent arteriolar resistance (RE), and glomerular pressure (PG)). During the regular sodium diet, MAP was lowered from 100 +/- 7 to 93 +/- 5 mmHg (p < 0.04) and the effective filtration pressure was lowered from 20 +/- 2 to 10 +/- 3 mmHg (p < 0.05); the renal plasma flow rate (pre: 560 +/- 74 vs. post: 627 +/- 108 mL/min) and glomerular filtration rate (82 +/- 10 vs. 78 +/- 5 mL/min) were not altered. RA remained unchanged (3,800 +/- 700 vs. 3,400 +/- 300 dyn.sec.cm-5; % reduction: 4 +/- 16%) whereas RE was reduced from 4,300 +/- 700 to 3,300 +/- 800 dyn.sec.cm-5 (19 +/- 15%). Thus, PG was lowered from 58 +/- 2 to 50 +/- 2 mmHg (13 +/- 3%), which parallels with the reduction in MAP.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009529 Nicardipine A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. Antagonil,Cardene,Cardene I.V.,Cardene SR,Dagan,Flusemide,Lecibral,Lincil,Loxen,Lucenfal,Nicardipine Hydrochloride,Nicardipine LA,Nicardipino Ratiopharm,Nicardipino Seid,Perdipine,Ridene,Vasonase,Y-93,Hydrochloride, Nicardipine,LA, Nicardipine,Y 93,Y93
D009578 Nitrobenzenes BENZENE derivatives carrying nitro group substituents.
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D012079 Renal Circulation The circulation of the BLOOD through the vessels of the KIDNEY. Kidney Circulation,Renal Blood Flow,Circulation, Kidney,Circulation, Renal,Blood Flow, Renal,Flow, Renal Blood
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D001798 Blood Proteins Proteins that are present in blood serum, including SERUM ALBUMIN; BLOOD COAGULATION FACTORS; and many other types of proteins. Blood Protein,Plasma Protein,Plasma Proteins,Serum Protein,Serum Proteins,Protein, Blood,Protein, Plasma,Protein, Serum,Proteins, Blood,Proteins, Plasma,Proteins, Serum

Related Publications

K Murakami, and G Kimura, and M Imanishi, and T Sanai, and Y Kawano, and S Kojima, and K Yoshida, and H Abe, and T Ashida, and H Yoshimi
January 1991, American journal of kidney diseases : the official journal of the National Kidney Foundation,
K Murakami, and G Kimura, and M Imanishi, and T Sanai, and Y Kawano, and S Kojima, and K Yoshida, and H Abe, and T Ashida, and H Yoshimi
January 1954, Deutsches Archiv fur klinische Medizin,
K Murakami, and G Kimura, and M Imanishi, and T Sanai, and Y Kawano, and S Kojima, and K Yoshida, and H Abe, and T Ashida, and H Yoshimi
January 1954, Klinische Wochenschrift,
K Murakami, and G Kimura, and M Imanishi, and T Sanai, and Y Kawano, and S Kojima, and K Yoshida, and H Abe, and T Ashida, and H Yoshimi
November 1993, Arzneimittel-Forschung,
K Murakami, and G Kimura, and M Imanishi, and T Sanai, and Y Kawano, and S Kojima, and K Yoshida, and H Abe, and T Ashida, and H Yoshimi
February 1993, American heart journal,
K Murakami, and G Kimura, and M Imanishi, and T Sanai, and Y Kawano, and S Kojima, and K Yoshida, and H Abe, and T Ashida, and H Yoshimi
August 1991, Circulation research,
K Murakami, and G Kimura, and M Imanishi, and T Sanai, and Y Kawano, and S Kojima, and K Yoshida, and H Abe, and T Ashida, and H Yoshimi
March 2004, American journal of hypertension,
K Murakami, and G Kimura, and M Imanishi, and T Sanai, and Y Kawano, and S Kojima, and K Yoshida, and H Abe, and T Ashida, and H Yoshimi
January 1992, Blood pressure. Supplement,
K Murakami, and G Kimura, and M Imanishi, and T Sanai, and Y Kawano, and S Kojima, and K Yoshida, and H Abe, and T Ashida, and H Yoshimi
February 1993, American heart journal,
K Murakami, and G Kimura, and M Imanishi, and T Sanai, and Y Kawano, and S Kojima, and K Yoshida, and H Abe, and T Ashida, and H Yoshimi
January 1992, Blood pressure. Supplement,
Copied contents to your clipboard!